

**Appendix 11 (as supplied by the authors): Risk of All-Cause Death, Major Adverse Cardiac Events, and Hospitalization for Acute Kidney Injury and Hyperkalemia Among Patients Using ARBs and ACEIs After Excluding Prevalent Users**

	Adjusted <sup>†</sup>	
	Hazard Ratio (95% CI)	P Value
<b>Intention-to-treat analysis</b>		
All-cause death	0.97 (0.87-1.07)	0.5
Major adverse cardiac events	0.88 (0.78-1.00)	0.06
Hospitalization for acute kidney injury	0.97 (0.83-1.12)	0.7
Hospitalization for hyperkalemia	1.13 (0.91-1.41)	0.3
<b>As-treated analysis</b>		
All-cause death	1.24 (0.91-1.69)	0.2
Major adverse cardiac events	0.84 (0.68-1.04)	0.1
Hospitalization for acute kidney injury	1.19 (0.90-1.58)	0.2
Hospitalization for hyperkalemia	1.10 (0.73-1.66)	0.7

<sup>†</sup> Adjusted for propensity score.

Abbreviations: CI, confidence interval; ARB, Angiotensin II receptor blockers; ACEI, angiotensin-converting-enzyme inhibitors.